- Home
- NTRA vs FTS Comparison
NTRA vs FTS Comparison
Compare NTRA & FTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- FTS
- Stock Information
- Founded
- NTRA 2003
- FTS 1885
- Country
- NTRA United States
- FTS Canada
- Employees
- NTRA N/A
- FTS N/A
- Industry
- NTRA Medical Specialities
- FTS Electric Utilities: Central
- Sector
- NTRA Health Care
- FTS Utilities
- Exchange
- NTRA Nasdaq
- FTS Nasdaq
- Market Cap
- NTRA 18.4B
- FTS 22.0B
- IPO Year
- NTRA 2015
- FTS N/A
- Fundamental
- Price
- NTRA $143.94
- FTS $45.25
- Analyst Decision
- NTRA Strong Buy
- FTS
- Analyst Count
- NTRA 17
- FTS 0
- Target Price
- NTRA $179.00
- FTS N/A
- AVG Volume (30 Days)
- NTRA 1.9M
- FTS 526.1K
- Earning Date
- NTRA 05-08-2025
- FTS 04-30-2025
- Dividend Yield
- NTRA N/A
- FTS 3.80%
- EPS Growth
- NTRA N/A
- FTS 4.62
- EPS
- NTRA N/A
- FTS 2.25
- Revenue
- NTRA $1,696,911,000.00
- FTS $7,998,109,588.00
- Revenue This Year
- NTRA $13.56
- FTS $14.64
- Revenue Next Year
- NTRA $18.11
- FTS $3.85
- P/E Ratio
- NTRA N/A
- FTS $20.12
- Revenue Growth
- NTRA 56.75
- FTS N/A
- 52 Week Low
- NTRA $83.13
- FTS $36.86
- 52 Week High
- NTRA $183.00
- FTS $46.06
- Technical
- Relative Strength Index (RSI)
- NTRA 41.35
- FTS 59.79
- Support Level
- NTRA $146.35
- FTS $44.24
- Resistance Level
- NTRA $155.64
- FTS $45.40
- Average True Range (ATR)
- NTRA 6.42
- FTS 0.62
- MACD
- NTRA 0.87
- FTS -0.05
- Stochastic Oscillator
- NTRA 51.93
- FTS 79.20
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About FTS Fortis Inc.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving more than 3.4 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.